Overview

Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Level

Status:
Completed
Trial end date:
2019-04-10
Target enrollment:
0
Participant gender:
All
Summary
Aim: To evaluate the effects of Valsartan versus Amlodipine on LV deformation in relation to plasma adiponectin and leptin levels in hypertensive individuals. Methods: LV strain measured by 2 dimensional speckle tracking echocardiography, plasma levels of adiponectin and leptin was determined in 30 healthy individuals served as control group and in 200 hypertensive patients before and after treatment for three months with either Valsartan 160 mg or amlodipine 10 mg.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Damanhour University
Collaborator:
Tanta University
Treatments:
Amlodipine
Valsartan
Criteria
Inclusion Criteria:

- Patients, of both sexes with mild to moderate essential hypertension (diastolic blood
pressure [DBP] >80 and ≤100 mmHg after a 2-week wash-out period, SBP systolic blood
pressure>120 and 160 mmHg). Another 30 healthy subjects are enrolled as control group.

Exclusion Criteria:

- Subjects with age < 18 years and >65 years and those with two and more
antihypertensive medications, those with diabetes, liver or kidney diseases, angina,
myocardial infarction or stroke within 6 months, congestive heart failure, neurologic
or psychiatric illness, secondary hypertension, known hypersensitivity to the drugs
used in the study. also those with conditions that may have caused metabolic
alterations within the past year (pregnancy, abdominal surgery, weight gain or loss of
more than 3 kg) are excluded.